300558.SZ
贝达药业
SZSE · Healthcare · C 制造业 · CN
CNY 48.53
−5.18%Year over year
Reported trailing growth
- Revenue
- +21.4%
- EBITDA
- —
- EBIT
- +39.5%
- EPS
- +8.5%
- Free cash flow
- -60.1%
- Operating cash flow
- -8.8%
Forward estimates
Based on analyst estimates
- Revenue
- -44.7%
- EBITDA
- -33.1%
- EPS
- -36.2%
Three-year CAGR
- Revenue
- +14.9%
- EBITDA
- +41.5%
- EBIT
- +64.0%
- Net income
- +28.1%
- EPS
- +27.8%
- Free cash flow
- +252.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026